Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
Stock Information for Digital Ally Inc.
Loading
Please wait while we load your information from QuoteMedia.